DOI: 10.2337/db07-0339
RAGE and Experimental Diabetic Neuropathy
1Department of Clinical Neurosciences and the Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada Background: Heightened expression of the receptor for advanced glycation end products (RAGE) contributes to development of systemic diabetic complications, but its contribution to diabetic neuropathy is uncertain. Objective: We studied experimental diabetic neuropathy and its relationship with RAGE expression using streptozotocin (STZ) diabetic mice including a RAGE-/- cohort exposed to long-term diabetes, as compared to littermates without diabetes.
Methods: Structural indices of neuropathy were addressed with serial (1, 3, 5 and 9 months of experimental diabetes) electrophysiological and quantitative morphometric analysis of dorsal root ganglia (DRG), peripheral nerve and epidermal innervation. RAGE protein and mRNA levels in DRG, peripheral nerve, and epidermal terminals were assessed in wildtype and RAGE-/- mice, with and without diabetes. The correlation of RAGE activation with nuclear factor
Results: Diabetic peripheral epidermal axons, sural axons, Schwann cells and sensory neurons within ganglia developed dramatic and cumulative rises in RAGE mRNA and protein along with progressive electrophysiological and structural abnormalities. RAGE-/- mice had attenuated structural features of neuropathy after 5 months of diabetes. RAGE-mediated signaling pathway activation for NF Conclusion: In a long-term model of experimental diabetes resembling human diabetic peripheral neuropathy, RAGE expression in the peripheral nervous system rises cumulatively, and relates to progressive pathological changes. Mice lacking RAGE have attenuated features of neuropathy and limited activation of potentially detrimental signaling pathways.
Correspondence: corytoth{at}shaw.ca
This article has been cited by other articles:
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||